Clopidogrel or Ticagrelor: Why, When, for Whom?
Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the cornerstone of the management of acute coronary syndromes. Despite its proven benefits, the choice of P2Y12 inhibitors remain to be debated over the decades because of the differences in efficacy and safety profiles among these agents. In this 60-minute session by the ISCP focusing on the A to Z of CV Pharmacotherapy, we will examine the differences between clopidogrel and ticagrelor, the two most widely used P2Y12 inhibitors worldwide. We will also identify the patient groups who can benefit most and discuss the optimal treatment duration.
This session is the fifth in a series of six webinars from the ISCP focusing on the A to Z of CV Pharmacotherapy. Led by moderators Craig Beavers (USA) and Franco Cheng (Hong Kong), it includes a speaker presentation from Diana A Gorog (UK) and a discussion from panellist Sotiris Antoniou (UK) that will examine the difference between two widely used P2Y12 inhibitors, clopidogrel and ticagrelor, through consideration of real-world examples, live discussions and audience Q&A.
This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.
This is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP) and co-produced in collaboration with Radcliffe Cardiology. The ISCP has been provided support to deliver this webinar by AstraZeneca UK through an unrestricted educational grant to cover organizational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.
This webinar is supported by
Clopidogrel or Ticagrelor: Why, When, for Whom?
11:30-12:30 ET/16:30-17:30 GMT/17:30-18:30 CET
- Welcome words
- Clopidogrel or Ticagrelor: Why, When, for Whom? Lecture by Dr Gorog
- Case 1 &2 Presentations & Panel Discussion
- Audience Q & A
Key Learning Objectives
- To evaluate and understand which patients should and should not be prescribed with clopidogrel and ticagrelor and which patients groups might benefit most;
- To review the pharmacokinetics of clopidogrel and ticagrelor and their potential drug-drug interactions;
- To analyse special and regional issues that impact the use of this drug;
- To apply evidence-based recommendations to two real world cases.
- Cardiovascular team members - doctors, nurses, pharmacists
- Family physicians
Professor Diana Gorog holds academic appointments at the University of Hertfordshire and at the National Heart and Lung Institute of Imperial College, London, and is a full-time interventional consultant cardiologist at East and North Hertfordshire NHS Trust, UK.
Prof Gorog graduated in Medicine from St. Bartholomew’s Medical School, University of London in1993 and undertook clinical training in major London teaching hospitals including the Hammersmith, Royal Brompton, St Mary’s, and Royal Free hospitals. She obtained both a postgraduate clinical research MD from the University of London Postgraduate Medical School, and a British Heart Foundation Fellowship in laboratory-based cardiac research at St Thomas’s/King’s College leading to a PhD, following which she returned to clinical cardiology to complete higher training in interventional cardiology.
She sees patients with all types of heart disease, including angina, hypertension, arrhythmias, heart failure and valvular heart disease. She undertakes coronary angiography and angioplasty, including complex coronary intervention. She is actively engaged in research, with a special interest in thrombosis and coronary angioplasty, preventing MI in at-risk patients.
Prof Gorog is the current Secretary of the Working Group on Thrombosis of the European Society of Cardiology.
Prof Gorog is on the Editorial Board of European Cardiology Review.
Mr Sotiris Antoniou is Consultant Pharmacist at Barts Heart Centre, part of Barts Health NHS Trust. Combined with his role as Lead Cardiovascular Pharmacist for UCL Partners supports medicines optimisation across the health economy to optimise patient outcomes and address unmet local needs. He is an independent prescriber and is currently chair of the cardiac committee for United Kingdom Clinical Pharmacy Association (UKCPA). He is chair of the DRM-foundation that supports the international Pharmacist Anticoagulation Taskforce (iPACT). A group aimed to improve pharmaceutical care around anticoagulants, by providing background materials and stimulating pharmacists to provide appropriate care to their patients.
He has published extensively in the medical press and has a particular interest in improving anticoagulation for stroke prevention in atrial fibrillation. Sotiris has been successful in obtaining a Lord Darzi funded fellow to ‘co-design and test a new referral pathway for people with atrial fibrillation with community pharmacists’ with the aim to support individuals' understanding of their condition and their therapy with the ultimate aim of optimising adherence.
He is actively involved in the training and development of clinical pharmacists including developing a curriculum and assessment tool for advanced and consultant level specialist cardiac pharmacists working with the UKCPA and Royal Pharmaceutical Society.
Mr Antoniou has served on many NICE development groups including Unstable Angina/NSTEMI guideline, stable angina and STEMI guidelines and is a current NICE TA member of the highly specialist technology appraisal group. He is also a member of the London Strategic Clinical Network Cardiovascular Leadership Group and NHS England Medicines Optimisation Intelligence Group meeting. Sotiris is also an honorary senior research associate at UCL School of Pharmacy.
Mr Franco Cheng is a lecturer at the Department of Pharmacology and Pharmacy at University of Hong Kong. Prior to joining HKU as a pharmacist in 2021, Franco worked in both private and public hospitals in Hong Kong with extensive exposure to cardiology.
He received his Bachelor's Degree in Pharmacy from The Chinese University of Hong Kong and then went on to study a Master in Clinical Pharmacy at the same institution.
Dr Craig Beavers graduated in 2009 from the University of Kentucky (UK) College of Pharmacy and completed a PGY1 pharmacy practice residency and a PGY2 cardiology pharmacy residency at UK Albert B. Chandler Hospital in Lexington, Kentucky (R365).
Dr Beavers is the Vice President of Operations for Baptist Health Paducah and is an Assistant Adjunct Professor with the University of Kentucky College of Pharmacy. He has worked as the Cardiovascular Clinical Pharmacy Coordinator at UK Healthcare. He has worked as Adjunct Faculty for Lipscomb University College of Pharmacy, University of Tennessee College of Pharmacy and served as the Director of Cardiovascular Services for the Hospital Corporation of America. He served as the postgraduate year two cardiology pharmacy residency programme at TriStar Centennial Medical Centre.
Dr Beavers currently serves as the Co-Chair of the Clinical Pharmacist Workgroup of the American College of Cardiology and as a Member of the Cardiovascular Team Council and Surviving Acute Myocardial Infarction Steering Committee.
He is the first pharmacist to be a Cardiovascular Professional for the Society for Cardiac Angiography and Interventions and serves on its Quality Committee. He has served as the Vice Chair and Chair of the ACCP Cardiology PRN Student and Resident Committee and currently serves as the PRN’s Secretary/ Treasurer.
He has published numerous papers, abstracts, and textbook chapters with a focus on cardiovascular pharmacotherapy. He is board certified in pharmacotherapy with added qualifications in cardiology and is a certified anticoagulation care provider. He is a fellow of the American Heart Association and an associate of the American College of Cardiology.